Former Armo Bio Exec Leveque Joins Synthorx as Chief Medical Officer

Synthorx has appointed Joseph Leveque to serve as chief medical officer of the San Diego biotech. Leveque most recently worked at Redwood City, CA-based cancer drug developer Armo Biosciences, which was acquired by Eli Lilly (NYSE: [[ticker:LLY]]) for $1.6 billion earlier this year. Leveque’s experience also includes senior roles at EMD Serono, Bristol-Myers Squibb (NYSE: [[ticker:BMY]]), and Onyx Pharmaceuticals. In April, Synthorx raised $63 million in a Series C financing round to advance Synthorin IL-2, its version of the cancer drug interleukin 2, into clinical testing.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.